Advertisement
Advertisement

ALZN

ALZN logo

Alzamend Neuro, Inc. Common Stock

1.46
USD
Sponsored
+0.09
+6.57%
Aug 10, 16:00 UTC -4
Closed
exchange

After-Market

1.47

+0.01
+0.34%

Alzamend Neuro, Inc. Common Stock Profile

About

Alzamed Neuro is an early clinical stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Their mission is to rapidly develop and market safe and effective treatments. Their current pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.

Info & Links

CEO

Stephan Jackman

Headquarters

3480 Peachtree Road NE, Second Floor Suite 103
Atlanta, GA 30326, UNITED STATES

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

https://www.alzamend.com

Auditor

HASKELL & WHITE LLP

Share holders

58

Employees

6

Alzamend Neuro, Inc. Common Stock Statistics

Valuation Measures

Market Capitalization2

7.02M

Enterprise Value

6.31M

Enterprise Value/EBITDA(ttm)

-0.73

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

--

Price to Book(mrq)

7.11

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

0.00%

Operating Margin(ttm)

--

Profit Margin(ttm)

0.00%

Return on Equity(ttm)

-277.74%

Return on Invested Capital(ttm)

-565.54%

Return on Assets(ttm)

-200.07%

Income Statement

Revenue(ttm)

0.00

Revenue Per Share(ttm)

0.00

Gross Profit(ttm)

0.00

EBITDA(ttm)3

-8.66M

Net Income Available to Common(ttm)

-8.77M

Diluted EPS(ttm)

-2.90

Share Statistics

Beta (5Y Monthly)

0.16

52-Week Change

-37.87%

S&P 500 52-Week Change

21.65%

S&P 500 Member

No

Stock Optionable

Yes

Total Shares Outstanding1

4.79M

Dividend Yield

0.00%

Float4

4.72M

% Held by Insiders

1.39%

% Held by Institutions

49.61%

Balance Sheet

Total Cash(mrq)

710.70K

Total Cash Per Share(mrq)

0.15

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

1.31%

Quick Ratio(mrq)

1.31%

Book Value Per Share(mrq)

0.17

Cash Flow

Operating Cash Flow Per Share(ytd)

-2.42

Free Cash Flow(ytd)

-8.07M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement